TB Education and Training Resource Guide—TREATMENT (Printable Version)
Return to Table of Contents
General Treatment
California Department of Health Services and California Tuberculosis
Controllers Association: Joint Guidelines for Tuberculosis Treatment and Control
This guideline offers comprehensive standards of evaluation and treatment of
patients with TB (California Department of Health Services, 1998).
Audience: health professionals
Format: guideline, 254 pp
Language: English
Available from: California Department of Health Services, Tuberculosis
Control Branch, 2151 Berkeley Way, Rm 608, Berkeley, CA 94704; www.dhs.cahwnet.gov/ps/dcdc/tbcb/tubindex.htm
Georgia Tuberculosis Reference Guide
This pocket guide serves as a basic clinical guide to TB infection, disease,
and control. Specific topics include the classification system for TB, tuberculin
skin testing, treatment of latent TB infection, current TB disease therapy,
TB prevention and treatment during pregnancy, childhood TB, TB and nursing homes,
the BCG vaccine, TB infection control in hospitals, and community TB control
(Emory University School of Medicine, 2001).
Audience: health professionals, physicians
Format: pocket guide, 83 pp
Language: English
Available from: Emory University School of Medicine, Division
of Infectious Diseases, 69 Butler St, SE, Atlanta, GA 30303; 404-616-6145; www.emory.edu/WHSC/MED
and Georgia Department of Human Resources, Division of Public
Health, Tuberculosis Control Program, 2 Peachtree St, 12th Fl, Atlanta, GA 30303;
404-657-2634; health.state.ga.us
Medication Information
Drug Resistance: Aminosalicyclic Acid (PAS) Granules for Treatment
This fact sheet provides information on the use of the second-line drug aminosalicyclic
acid (PAS) granules for the treatment of persons with multidrug-resistant TB.
It discusses the dosing regimen for PAS and possible adverse reactions (New
York City Department of Health, 2001).
Audience: health professionals, physicians
Format: fact sheet, 1 p
Language: English
Internet link: www.nyc.gov/html/doh/html/tb/tb4b.html
Available from: New York City Department of Health and Mental
Hygiene, Tuberculosis Control Program, 125 Worth St, New York, NY 10013; 212-442-9968;
www.nyc.gov/html/doh/html/tb/tb.html
Ethambutol HCL
This fact sheet provides information about ethambutol HCL and its use in treating
TB (VersaPharm, Inc., 2001).
Audience: physicians
Format: fact sheet, 2 pp
Language: English
Available from: VersaPharm, Inc., PO Box 7509, Marietta, GA
30065-1509; 800-548-0700; www.versapharm.com
Impact of HIV Protease Inhibitors on the Treatment of HIV-Infected
Tuberculosis Patients with Rifampin. Morbidity and Mortality Weekly Report.
45(42):921-925, October 25, 1996 
This report describes approaches for managing patients who are candidates for
or who are undergoing protease inhibitor therapy when TB is diagnosed (Centers
for Disease Control and Prevention, 1996).
Audience: health professionals, nurses, physicians
Format: report, 5 pp
Language: English
Internet link: www.cdc.gov/nchstp/tb/pubs/mmwrhtml/mmwr_hivaids.htm
Available from: Massachusetts Medical Society, 860 Winter St,
Waltham Woods Corporate Center, Waltham, MA 02451-1411; 800-843-6356; www.massmed.org.
Paper copies of single issues cost $5.25.
and U.S. Government Printing Office (GPO), Washington, D.C.
20402; 866-512-1800; www.gpo.gov. GPO provides
a CD-ROM containing MMWRs from 1991 to 1997 for $19. Request item #017-022-01418-1.
Isoniazid Tablets
This fact sheet provides information about isoniazid and its use in treating
TB (VersaPharm, Inc., 2001).
Audience: physicians
Format: fact sheet, 2 pp
Language: English
Available from: VersaPharm, Inc., PO Box 7509, Marietta, GA
30065-1509; 800-548-0700; www.versapharm.com
Management: The Importance of Rifampin
This fact sheet examines the role of rifampin in TB treatment, outlines and
describes the side effects of the drug, and provides an overview of rifabutin,
including its use as a replacement drug for individuals who cannot take rifampin
(New York City Department of Health, 2001).
Audience: health professionals, physicians
Format: fact sheet, 2 pp
Language: English
Internet link: www.nyc.gov/html/doh/html/tb/tb2d.html
Available from: New York City Department of Health and Mental
Hygiene, Tuberculosis Control Program, 125 Worth St, New York, NY 10013; 212-442-9968;
www.nyc.gov/html/doh/html/tb/tb.html
Management: Rifater and Rifamate in the Treatment of TB
This fact sheet discusses the use of the drugs rifampin and rifamate in the
treatment of individuals with TB. It explains how combination drugs can help
maintain adherence among patients who cannot participate in DOT (New York City
Department of Health, 2001).
Audience: health professionals, physicians
Format: fact sheet, 2 pp
Language: English
Internet link: www.nyc.gov/html/doh/html/tb/tb2e.html
Available from: New York City Department of Health and Mental
Hygiene, Tuberculosis Control Program, 125 Worth St, New York, NY 10013; 212-442-9968;
www.nyc.gov/html/doh/html/tb/tb.html
Pocket Guide to Antituberculosis Drugs
This pocket guide describes medications for treating TB and discusses monitoring
patients. It contains a table that lists drugs commonly prescribed and adverse
reactions (University of Texas Health Center at Tyler, 1998).
Audience: health professionals, physicians
Format: pocket guide, 10 pp
Language: English
Available from: University of Texas Health Center at Tyler,
Center for Pulmonary and Infectious Disease Control, 11937 U.S. Hwy 271, Tyler,
TX 75708-3154; 903-877-3451; research.uthct.edu/cpidc
Pyrazinamide
This fact sheet provides information about pyrazinamide and its use in treating
TB (VersaPharm, Inc., 2001).
Audience: physicians
Format: fact sheet, 2 pp
Language: English
Available from: VersaPharm, Inc., PO Box 7509, Marietta, GA
30065-1509; 800-548-0700; www.versapharm.com
Pyrioxine HCL
This fact sheet provides information about pyrioxine HCL and its use in treating
TB (VersaPharm, Inc., 2001).
Audience: physicians
Format: fact sheet, 2 pp
Language: English
Available from: VersaPharm, Inc., PO Box 7509, Marietta, GA
30065-1509; 800-548-0700; www.versapharm.com
Rifampin Capsules, USP
This fact sheet provides information about rifampin and its use in treating
TB (VersaPharm, Inc., 2001).
Audience: physicians
Format: fact sheet, 2 pp
Language: English
Available from: VersaPharm, Inc., PO Box 7509, Marietta, GA
30065-1509; 800-548-0700; www.versapharm.com
Treatment of Tuberculosis: Standard Therapy for Active Disease
This pamphlet provides dosage, adverse reactions, monitoring, and general information
on 4 first-line and 12 second-line medications for active TB disease (New Jersey
Medical School, National Tuberculosis Center, 2000).
Audience: health professionals, physicians
Format: pamphlet, 6 pp
Language: English
Internet link: www.umdnj.edu/ntbcweb/docs/drug%20card.pdf
Available from: University of Medicine and Dentistry of New
Jersey, New Jersey Medical School, National Tuberculosis Center, 225 Warren
St, First Fl, West Wing, PO Box 1709, Newark, NJ 07101-1709; 973-972-0979; www.umdnj.edu/ntbcweb
Tuberculosis Medication Card for Outreach Workers
This pocket guide provides information about medications used to treat TB (New
York State Department of Health, 2000).
Audience: health professionals, outreach workers, social service
providers
Format: pocket guide, 4 pp
Language: English
Available from: New York State Department of Health, Bureau
of TB Control, Corning Tower, Rm 840, Empire State Plaza, Albany, NY 12237-0669;
518-474-4845; www.health.state.ny.us/home.html
Tuberculosis Treatment Card for Clinicians
This pocket guide provides information about medications used to treat TB and
identifies various first-line, second-line, and combination anti-TB medications
(New York State Department of Health, 2000).
Audience: health professionals, physicians
Format: pocket guide, 4 pp
Language: English
Available from: New York State Department of Health, Bureau
of TB Control, Corning Tower, Rm 840, Empire State Plaza, Albany, NY 12237-0669;
518-474-4845; www.health.state.ny.us/home.html
Patient Adherence
Approaches to Improving Adherence to Antituberculosis Therapy-South
Carolina and New York, 1986-1991. Morbidity and Mortality Weekly Report.
42(04):72-75, 81, February 5, 1993
This report describes the experiences of selected strategies in South Carolina
and New York City for improving patient adherence to anti-TB therapy by using
a combination of strategies that included incentives, DOT, court-ordered DOT,
and commitment from inpatient management (Centers for Disease Control and Prevention,
1993).
Audience: health professionals, nurses, physicians
Format: report, 3 pp
Language: English
Internet link: www.cdc.gov/nchstp/tb/pubs/mmwrhtml/mmwr_adherence.htm
Available from: Massachusetts Medical Society, 860 Winter St,
Waltham Woods Corporate Center, Waltham, MA 02451-1411; 800-843-6356; www.massmed.org.
Paper copies of single issues cost $5.25.
and U.S. Government Printing Office (GPO), Washington, D.C.
20402; 866-512-1800; www.gpo.gov. GPO provides
a CD-ROM containing MMWRs from 1991 to 1997 for $19. Request item #017-022-01418-1.
Enablers and Incentives
The book discusses how enablers and incentives help promote patient compliance
in TB treatment programs, who is eligible to receive enablers and incentives,
what can be used in this capacity to encourage patient adherence, and how to
ease patients out of this type of program (South Carolina Department of Health
and Environmental Control, 1989).
Audience: government agencies, health professionals
Format: book, 38 pp
Language: English
Available from: Oregon Health Services, Tuberculosis Program,
PO Box 14450, Portland, OR 97214; 503-731-4029; www.ohd.hr.state.or.us/welcome.htm
and South Carolina Department of Health and Environmental
Control, 1751 Calhoun St, Columbia, SC 29201-2606; 803-898-0558; www.scdhec.net/hs/diseasecont/tb/html
Improving Patient Adherence to Tuberculosis Treatment
This book, available online only, provides information on improving patient
adherence to medication and follow-up care by providing steps on measuring,
predicting, and improving compliance (Centers for Disease Control and Prevention,
1994).
Audience: health professionals
Format: book, 56 pp
Language: English
Internet link: www.cdc.gov/nchstp/tb/pubs/adherence/default.htm
Infection Control: Commissioner's Orders for Adherence to Anti-TB Treatment
This fact sheet provides information on New York City regulations to ensure
the completion of medical treatment for TB (New York City Department of Health,
2001).
Audience: health professionals, physicians
Format: fact sheet, 2 pp
Language: English
Internet link: www.nyc.gov/html/doh/html/tb/tb5a.html
Available from: New York City Department of Health and Mental
Hygiene, Tuberculosis Control Program, 125 Worth St, New York, NY 10013; 212-442-9968;
www.nyc.gov/html/doh/html/tb/tb.html
Management: Completion of Treatment for Tuberculosis
This fact sheet provides information about the standard duration of treatment
for TB and strategies to improve patient adherence to treatment. It reviews
CDC guidelines, promotes the use of DOT and rifamycin for optimal treatment
results, and discusses cases that may call for more than 6 months of therapy
(New York City Department of Health, 2001).
Audience: health professionals, physicians
Format: fact sheet, 2 pp
Language: English
Internet link: www.nyc.gov/html/doh/html/tb/tb2k.html
Available from: New York City Department of Health and Mental
Hygiene, Tuberculosis Control Program, 125 Worth St, New York, NY 10013; 212-442-9968;
www.nyc.gov/html/doh/html/tb/tb.html
TB Pill Count Report Form
This form is used to monitor and to assure that a person with TB is taking his/her
prescribed medication (County of San Diego Health and Human Services Agency,
1989).
Audience: health professionals, nurses, persons with TB
Format: tool, 1 p
Language: English
Available from: County of San Diego Health and Human Services
Agency, Office of Public Health, Tuberculosis Control Program, PO Box 85222,
San Diego, CA 92816; 619-692-5565; www.co.san-diego.ca.us/cnty/cntydepts/health/services/tb/index.htm
Latent TB Infection
Diagnosis and Treatment of Latent Tuberculosis Infection in the 21st
Century: An Audio Recording for Clinicians
This audiotape, CD-ROM, and study guide discuss the diagnosis and treatment
of latent TB infection. The CD-ROM presents the major risk factors for developing
active TB disease once latent TB infection has been contracted (Francis J. Curry
National Tuberculosis Center, 2000).
Audience: health professionals, nurses, physicians
Format: audiotape; study guide (includes CD-ROM)
Language: English
Available from: Francis J. Curry National Tuberculosis Center,
3180 18th St, Ste 101, San Francisco, CA 94110-2028; 415-502-4600; www.nationaltbcenter.edu.
Improving Treatment Completion for Latent Tuberculosis Infection among
Health Care Workers
This book describes the procedures used in the Fast Track program, a program
of the Charles P. Felton National Tuberculosis Center of Harlem Hospital that
provides treatment for health care workers with latent TB infection, and delineates
methods that may be useful for other institutions to develop similar programs
(Charles P. Felton National Tuberculosis Center, 1999).
Audience: health professionals, physicians
Format: book, 31 pp
Language: English
Available from: Charles P. Felton National Tuberculosis Center
at Harlem Hospital, 2238 Fifth Ave, First Fl, New York, NY 10037; 212-939-8254;
www.harlemtbcenter.org
Notice to Readers: Use of Short-Course Tuberculosis Preventive Therapy
Regimens in HIV-Seronegative Persons. Morbidity and Mortality Weekly Report.
47(42):911-912, October 30, 1998
This report notes that a trial of the pyrazinamide regimen for TB in HIV-negative
persons has not been conducted and that additional data will be needed on acceptability
and toxicity to determine whether it is a cost-effective alternative to longer
courses of isoniazid (Centers for Disease Control and Prevention, 1998).
Audience: health professionals, nurses, physicians
Format: report, 2 pp
Language: English
Internet link: www.cdc.gov/nchstp/tb/pubs/mmwrhtml/mmwr_treatment.htm
Available from: Massachusetts Medical Society, 860 Winter St,
Waltham Woods Corporate Center, Waltham, MA 02451-1411; 800-843-6356; www.massmed.org.
Paper copies of single issues cost $5.25.
Pocket Guide to Preventive Therapy
This pocket guide explains how to determine whether a patient with TB is eligible
for preventive therapy. It discusses special considerations for children, adults,
persons infected with HIV, and patients who display fibrosis on their chest
X-ray (University of Texas Health Center at Tyler, 1998).
Audience: health professionals, physicians
Format: pocket guide, 2 pp
Language: English
Available from: University of Texas Health Center at Tyler,
Center for Pulmonary and Infectious Disease Control, 11937 U.S. Hwy 271, Tyler,
TX 75708-3154; 903-877-3451; research.uthct.edu/cpidc
Prevention: Identifying and Treating "Old Tuberculosis"
This fact sheet provides information on the treatment and evaluation of individuals
with latent TB infection. It outlines multidrug treatment and discusses the
tests that need to be administered before a patient begins such treatment. It
also discusses radiographic findings associated with risk for TB (New York City
Department of Health, 2001).
Audience: health professionals, physicians
Format: fact sheet, 2 pp
Language: English
Internet link: www.nyc.gov/html/doh/html/tb/tb3c.html
Available from: New York City Department of Health and Mental
Hygiene, Tuberculosis Control Program, 125 Worth St, New York, NY 10013; 212-442-9968;
www.nyc.gov/html/doh/html/tb/tb.html
Prevention: Treatment of Latent TB Infection for Persons at Risk for
Developing TB Disease
This fact sheet discusses risk factors for progression to TB disease, treatment
for latent TB infection, and New York City services for persons requiring treatment
(New York City Department of Health, 2000).
Audience: health professionals, physicians
Format: fact sheet, 2 pp
Language: English
Internet link: www.nyc.gov/html/doh/html/tb/tb3b.html
Available from: New York City Department of Health and Mental
Hygiene, Tuberculosis Control Program, 125 Worth St, New York, NY 10013; 212-442-9968;
www.nyc.gov/html/doh/html/tb/tb.html
Targeted Testing and Treatment for Latent TB Infection
This fact sheet presents information about testing and treating individuals
with latent TB infection and recommends that health professionals test individuals
who are at high risk for TB and link that testing to treatment as appropriate
(Massachusetts Department of Public Health, 2000).
Audience: health professionals, nurses, physicians
Format: fact sheet, 2 pp
Language: English
Available from: Massachusetts Department of Public Health,
Division of Tuberculosis Control, 305 South St, Jamaica Plain, MA 02130; 617-983-6970;
www.state.ma.us/dph/dphhome.htm
Targeted Tuberculin Testing and Treatment of Latent Tuberculosis Infection.
Morbidity and Mortality Weekly Report. 49(RR-06), June 9, 2000
This guideline provides new recommendations for targeted tuberculin testing
and treatment regimens for persons with latent TB infection and updates previously
published guidelines (Centers for Disease Control and Prevention, 2000).
Audience: health professionals, nurses, physicians
Format: guideline, 71 pp
Language: English
Internet link: www.cdc.gov/nchstp/tb/pubs/mmwrhtml/maj_guide.htm.
Available from: CDC National Center for HIV, STD, and TB Prevention
(NCHSTP). Materials can be ordered in a number of ways: 1) By accessing the
online order form at www.cdc.gov/nchstp/tb.
2) by calling the CDC voice and fax information system (recording) toll-free
at 888-232-3228, then pressing options 2, 5, 1, 2, 2; 3) by faxing a request
for material to the NCHSTP Office of Communications at 404-639-8910; or 4) by
mailing a request to the CDC NCHSTP Office of Communications at 1600 Clifton
Rd, NE, MS E-07, Atlanta, GA 30333. Request item #00-6422.
and CDC National Prevention Information Network, PO Box 6003,
Rockville, MD 20849-6003; 800-458-5231; www.cdcnpin.org.
Request inventory item #M036.
and Massachusetts Medical Society, 860 Winter St, Waltham
Woods Corporate Center, Waltham, MA 02451-1411; 800-843-6356; www.massmed.org.
Paper copies of single issues cost $5.25.
Testing and Treatment for Latent Tuberculosis Infection
This newsletter examines issues related to the testing and treatment of individuals
with latent TB infection. It outlines 10 basic components of testing and treatment,
which include knowing when to test, reading a tested area, testing special groups,
and treating special groups (New York City Department of Health, 2000).
Audience: health professionals, nurses, physicians
Format: newsletter, 8 pp
Language: English
Internet link: www.nyc.gov/html/doh/pdf/chi/chi19-3.pdf
Available from: New York City Department of Health and Mental
Hygiene, Tuberculosis Control Program, 125 Worth St, New York, NY 10013; 212-442-9968;
www.nyc.gov/html/doh/html/tb/tb.html
Treating Latent Tuberculosis Infection in Key High-Risk Communities
Toolbox
These tools are primarily for urban TB programs wishing to improve secondary
prevention of TB in those groups at highest risk of progression to TB disease,
including the homeless, chemically dependent, and mentally ill. It discusses:
the rationale for DOT of latent TB infection, the San Francisco Tuberculosis
Outreach and Prevention Program and other successful models, essential components
for a successful program with high completion rates, and community collaboration
(Francis J. Curry National Tuberculosis Center, 2003).
Audience: health professionals
Format: CD-ROM
Language: English
Available from: Francis J. Curry National Tuberculosis Center,
3180 18th St, Ste 101, San Francisco, CA 94110-2028; 415-502-4600; www.nationaltbcenter.edu.
Treatment of Latent Tuberculosis Infection (LTBI) (with revised guidelines
for RIF-PZA)
This pocket guide and poster provide information about treating latent TB infection,
identify those who should undergo tuberculin skin testing, and provide a chart
of recommended drug regimens (Charles P. Felton National Tuberculosis Center,
2001).
Audience: health professionals, nurses, physicians
Format: pocket guide, 4 pp; poster, 13" X 19.5"
Language: English
Available from: Charles P. Felton National Tuberculosis Center
at Harlem Hospital, 2238 Fifth Ave, First Fl, New York, NY 10037; 212-939-8254;
www.harlemtbcenter.org
Treatment of Latent Tuberculosis Infection (LTBI) in Children and Adolescents
(with revised guidelines for RIF-PZA)
This pocket guide and poster provide a table for recommended drug regimens for
treating latent TB infection in children and adolescents. They show each type
of drug used, its interval and duration, pediatric dosage, and criteria for
completing drug therapy (Charles P. Felton National Tuberculosis Center, 2002).
Audience: health professionals, nurses, physicians
Format: pocket guide, 4 pp; poster, 13" X 19.5"
Language: English
Internet link: www.harlemtbcenter.org/dept/harlemtb/pediatric.pdf
Available from: Charles P. Felton National Tuberculosis Center
at Harlem Hospital, 2238 Fifth Ave, First Fl, New York, NY 10037; 212-939-8254;
www.harlemtbcenter.org
Treatment of Latent Tuberculosis Infection (LTBI) in Pregnancy/Postpartum
(with revised guidelines for RIF-PZA)
This pocket guide and poster provide a table for recommended drug regimens for
treating latent TB infection in pregnancy/postpartum. They show each type of
drug used, its interval and duration, adult maximum dosage, and criteria for
completing drug therapy (Charles P. Felton National Tuberculosis Center, 2001).
Audience: health professionals, nurses, physicians
Format: pocket guide, 4 pp; poster, 13" X 10.5"
Language: English
Internet link: www.harlemcenter.org/dept/harlemtb/pregnancy.pdf
Available from: Charles P. Felton National Tuberculosis Center
at Harlem Hospital, 2238 Fifth Ave, First Fl, New York, NY 10037; 212-939-8254;
www.harlemtbcenter.org
Treatment of Latent Tuberculosis Infection (Preventive Therapy)
This fact sheet, available online or via fax only, discusses who should receive
treatment, regimen options for HIV-infected persons as well as those not infected,
and monitoring (Centers for Disease Control and Prevention, 2001).
Audience: health professionals, nurses, physicians
Format: fact sheet, 4 pp
Language: English
Internet link: www.cdc.gov/nchstp/tb/pubs/dtbefax.htm.
Available from: Centers for Disease Control and Prevention.
To receive this document by fax, call 888-CDC-FAXX (888-232-3299). At the prompt,
request item #250110.
Tuberculosis Management Clinic: INH Evaluation/Initiation
This form is an evaluation guide for considering the use of isoniazid for TB
patients (Multnomah County Health Department, 1996).
Audience: health professionals
Format: tool, 1 p
Language: English
Available from: Multnomah County Health Department, 1120 SW
Fifth Ave, Suite 1400, Portland, OR 97204; 503-988-3674; www.co.multnomah.or.us/health
Tuberculosis (TB): Targeted Testing and Treatment of Latent TB Infection
This fact sheet discusses targeting TB skin testing and medical treatments for
latent TB infection (Florida Department of Health, 2000).
Audience: health professionals, hospitals, physicians
Format: fact sheet, 2 pp
Language: English
Available from: Florida Department of Health, Bureau of TB
and Refugee Health, 4052 Bald Cypress Way, BIN A20, Tallahassee, FL 32399-1717;
850-245-4350; www.doh.state.fl.us
Update: Fatal and Severe Hepatitis Associated with Rifampin and Pyrazinamide
for the Treatment of Latent Tuberculosis Infection-New York and Georgia, 2000.
Morbidity and Mortality Weekly Report. 50(15):289-291, April 20, 2001
This report discusses two cases of latent TB infection in which patients developed
severe or fatal hepatitis associated with rifampin-pyrazinamide (RIF-PZA) treatment
(Centers for Disease Control and Prevention, 2001).
Audience: health professionals, nurses, physicians
Format: report, 3 pp
Language: English
Internet link: www.cdc.gov/nchstp/tb/pubs/mmwrhtml/mmwr_treatment.htm
Available from: Massachusetts Medical Society, 860 Winter St,
Waltham Woods Corporate Center, Waltham, MA 02451-1411; 800-843-6356; www.massmed.org.
Paper copies of single issues cost $5.25.
Update: Fatal and Severe Liver Injuries Associated with Rifampin and
Pyrazinamide for Latent Tuberculosis Infection, and Revisions in American Thoracic
Society/CDC Recommendations-United States, 2001. Morbidity and Mortality
Weekly Report. 50(34):733-735, August 31, 2001
This report provides preliminary information about 21 cases of liver injury
associated with rifampin-pyrazinamide (RIF-PZA) and the revised recommendations
on selecting appropriate therapy for patients with latent TB infection and monitoring
the use of RIF-PZA to treat infection (Centers for Disease Control and Prevention,
2001).
Audience: health professionals, nurses, physicians
Format: report, 3 pp
Language: English
Internet link: www.cdc.gov/nchstp/tb/pubs/mmwrhtml/mmwr_treatment.htm
Available from: Massachusetts Medical Society, 860 Winter St,
Waltham Woods Corporate Center, Waltham, MA 02451-1411; 800-843-6356; www.massmed.org.
Paper copies of single issues cost $5.25.
TB Disease Treatment
Clinical Update: Impact of HIV Protease Inhibitors on the Treatment
of HIV-Infected Tuberculosis Patients with Rifampin. Morbidity and Mortality
Weekly Report. 45(42):921-925, October 25, 1996
This report describes approaches for managing patients who are candidates for
or who are undergoing protease inhibitor therapy when TB is diagnosed. It presents
interim recommendations for managing these patients until additional data are
available and formal guidelines are issued regarding the use of rifampin in
conjunction with protease inhibitors (Centers for Disease Control and Prevention,
1996).
Audience: health professionals, nurses, physicians
Format: report, 5 pp
Language: English
Internet link: www.cdc.gov/nchstp/tb/pubs/mmwrhtml/mmwr_treatment.htm
Available from: Massachusetts Medical Society, 860 Winter St,
Waltham Woods Corporate Center, Waltham, MA 02451-1411; 800-843-6356; www.massmed.org.
Paper copies of single issues cost $5.25.
and U.S. Government Printing Office (GPO), Washington, D.C.
20402; 866-512-1800; www.gpo.gov. GPO provides
a CD-ROM containing MMWRs from 1991 to 1997 for $19. Request item #017-022-01418-1.
Management: Completion of Treatment for Tuberculosis
This fact sheet discusses the standard duration of treatment for TB and ways
to ensure adherence to treatment (New York City Department of Health, 2001).
Audience: health professionals, physicians
Format: fact sheet, 2 pp
Language: English
Internet link: www.nyc.gov/html/doh/html/tb/tb2k.html
Available from: New York City Department of Health and Mental
Hygiene, Tuberculosis Control Program, 125 Worth St, New York, NY 10013; 212-442-9968;
www.nyc.gov/html/doh/html/tb/tb.html
Timeline for the Management of TB Suspects/Cases
This fact sheet illustrates the timeline for various treatment regimens and
monitoring techniques for persons with TB. It includes a timeline for drug regimens,
providers visits, sputum specimens, chest X-rays, and baseline and follow-up
tests (Oregon Health Services, 2002).
Audience: health professionals
Format: fact sheet, 1 p
Language: English
Available from: Oregon Health Services, Tuberculosis Program,
PO Box 14450, Portland, OR 97214; 503-731-4029; www.ohd.hr.state.or.us/welcome.htm
Treatment of Tuberculosis Disease in Non-HIV-infected Persons
This fact sheet, available online or via fax only, discusses regimen options
for treating TB in people not infected with HIV. It also discusses adverse reactions,
case management, and special situations such as extrapulmonary TB, TB in pregnant
or lactating women, TB in children, and drug-resistant TB (Centers for Disease
Control and Prevention, 1999).
Audience: health professionals, nurses, occupational health
and infection control workers, physicians
Format: fact sheet, 4 pp
Language: English
Internet link: www.cdc.gov/nchstp/tb/pubs/dtbefax.htm.
Available from: Centers for Disease Control and Prevention.
To receive this document by fax, call 888-CDC-FAXX (888-232-3299). At the prompt,
request item #250111.
Treatment of Tuberculosis (TB) in Adult and Adolescent Patients Co-Infected
with the Human Immunodeficiency Virus (HIV)
This information card identifies drugs used to treat TB and HIV/AIDS. It examines
the induction phase of each drug's duration as well as the continuation phase
of a high- and low-dosage rifabutin-based treatment regimen for persons with
TB and HIV (New Jersey Medical School, National Tuberculosis Center, 2001).
Audience: health professionals, physicians
Format: information card, 6 pp
Language: English
Available from: University of Medicine and Dentistry of New
Jersey, New Jersey Medical School, National Tuberculosis Center, 225 Warren
St, First Fl, West Wing, PO Box 1709, Newark, NJ 07101-1709; 973-972-0979; www.umdnj.edu/ntbcweb
Treatment of Tuberculosis and Tuberculosis Infection in Adults and
Children. American Journal of Respiratory and Critical Care Medicine.
149:1359-1374, January 1, 1994
This guideline overviews TB drug regimens in current use and potentially effective
regimens not yet widely used in the treatment of TB and TB infection in U.S.
adults and children (American Thoracic Society and the Centers for Disease Control
and Prevention, 1994).
Audience: physicians
Format: guideline, 16 pp
Language: English
Internet link: www.cdc.gov/nchstp/tb/pubs/mmwrhtml/maj_guide.htm.
Available from: CDC National Center for HIV, STD, and TB Prevention
(NCHSTP). Materials can be ordered in a number of ways: 1) By accessing the
online order form at www.cdc.gov/nchstp/tb.
2) by calling the CDC voice and fax information system (recording) toll-free
at 888-232-3228, then pressing options 2, 5, 1, 2, 2; 3) by faxing a request
for material to the NCHSTP Office of Communications at 404-639-8910; or 4) by
mailing a request to the CDC NCHSTP Office of Communications at 1600 Clifton
Rd, NE, MS E-07, Atlanta, GA 30333. Request item #00-6453.
Tuberculosis Treatment
This newsletter examines issues related to testing and treating individuals
with active TB. It outlines the basic components of active TB testing, treatment,
and prevention, and it discusses reporting, combination therapy, and ongoing
care and treatment for individuals with multidrug-resistant TB (New York City
Department of Health, 2000).
Audience: health professionals, nurses, physicians
Format: newsletter, 8 pp
Language: English
Internet link: www.nyc.gov/html/doh/pdf/chi/chi18-2.pdf
Available from: New York City Department of Health and Mental
Hygiene, Tuberculosis Control Program, 125 Worth St, New York, NY 10013; 212-442-9968;
www.nyc.gov/html/doh/html/tb/tb.html
Directly Observed Therapy (DOT)
Directly Observed Therapy (DOT) and Directly Observed Preventive Therapy
(DOPT): What It Is and What It Is Not
This fact sheet clarifies the use of DOT and DOPT in the treatment of TB infection
and disease. It explains how to administer DOT and DOPT and dispels myths and
misinformation about them (University of Texas Health Center at Tyler, 1997).
Audience: health professionals
Format: fact sheet, 4 pp
Language: English
Available from: University of Texas Health Center at Tyler,
Center for Pulmonary and Infectious Disease Control, 11937 U.S. Hwy 271, Tyler,
TX 75708-3154; 903-877-3451; research.uthct.edu/cpidc
Directly Observed Therapy (DOT) Training Curriculum for TB Control
Programs
This training curriculum is designed to improve the skills of DOT workers in
public health TB control programs. It addresses skills required to conduct DOT
such as promoting patient adherence to TB treatment, protecting patient confidentiality,
and working with culturally diverse populations. The curriculum includes a trainer's
guide and participant materials, as well as handouts, training outlines, slide
presentations, and an educational videotape (Francis J. Curry National Tuberculosis
Center).
Audience: health educators/communicators, managers and supervisors
Format: teaching guide (videotape, CD-ROM)
Language: English
Available from: Francis J. Curry National Tuberculosis Center,
3180 18th St, Ste 101, San Francisco, CA 94110-2028; 415-502-4600; www.nationaltbcenter.edu.
Directly Observed Therapy: It Can Help You Cure TB
This pamphlet for physicians explains DOT, who needs DOT, and how to arrange
for DOT (New York State Department of Health, 2001).
Audience: physicians
Format: pamphlet, 2 pp
Language: English
Available from: New York State Department of Health, Bureau
of TB Control, Corning Tower, Rm 840, Empire State Plaza, Albany, NY 12237-0669;
518-474-4845; www.health.state.ny.us/home.html
Guidelines for Initiating a School-Based Directly Observed Therapy
Program
This pamphlet provides guidelines on initiating a school-based DOT program for
TB. Topics include followup during course of treatment, collaboration and communications
between the DOT coordinator and school nurse, and quality assurance (New Jersey
Medical School, National Tuberculosis Center, 2002).
Audience: community leaders, government agencies, health professionals,
nurses, physicians
Format: pamphlet, 16 pp
Language: English
Available from: University of Medicine and Dentistry of New
Jersey, New Jersey Medical School, National Tuberculosis Center, 225 Warren
St, First Fl, West Wing, PO Box 1709, Newark, NJ 07101-1709; 973-972-0979;www.umdnj.edu/ntbcweb
An Introduction to DOT Fieldwork
This videotape discusses TB and the role of DOT fieldwork in treatment (New
York State Department of Health, 2001).
Audience: community leaders, health professionals, social
service providers
Format: videotape, 22 min
Language: English
Available from: New York State Department of Health, Bureau
of TB Control, Corning Tower, Rm 840, Empire State Plaza, Albany, NY 12237-0669;
518-474-4845; www.health.state.ny.us/home.html
Management: Directly Observed Therapy
This fact sheet discusses the use of DOT for a person with TB. It identifies
the advantages of DOT and describes intermittent therapy by DOT (New York City
Department of Health, 2001).
Audience: health professionals, physicians
Format: fact sheet, 2 pp
Language: English
Internet link: www.nyc.gov/html/doh/html/tb/tb2a.html
Available from: New York City Department of Health and Mental
Hygiene, Tuberculosis Control Program, 125 Worth St, New York, NY 10013; 212-442-9968;
www.nyc.gov/html/doh/html/tb/tb.html
Tuberculosis Case Management
This CD-ROM discusses TB infection, active TB disease, and the use of DOT. It
also discusses drugs used in DOT and their side effects (Center for Human Services,
2000).
Audience: health professionals
Format: CD-ROM
Language: English
Internet link: www.qaproject.org
Available from: Quality Assurance Project, 7200 Wisconsin Ave,
Ste 600, Bethesda, MD 20814; 301-654-8338; www.qaproject.org
Adverse Reactions
TB Rash Evaluation
This rash evaluation sheet is used to assist the nurse or physician diagnosing
a TB medication reaction. The sheet lists TB medications and provides patients
with space to indicate the drugs they use or have used (Multnomah County Health
Department, 1993).
Audience: nurses, physicians
Format: tool
Language: English
Available from: Multnomah County Health Department, 1120 SW
Fifth Ave, Suite 1400, Portland, OR 97204; 503-988-3674; www.co.multnomah.or.us/health
